Search research articles
Contact Us
Filters
Showing results (1-10 of 71) with videos related to
Page
of 8
Sort By:
The Primary Care Companion for CNS Disorders
|
March 24, 2018
Galantamine-Memantine Combination for Cognitive Impairments Due to Electroconvulsive Therapy, Traumatic Brain Injury, and Neurologic and Psychiatric Disorders: Kynurenic Acid and Mismatch Negativity Target Engagement
Maju Mathew Koola
Schizophrenia Research
|
November 27, 2018
Can N‑acetylcysteine, varenicline, or the combination prevent psychosis by enhancing mismatch negativity?
Maju Mathew Koola
Indian Journal of Psychological Medicine
|
April 27, 2016
Cytokines in Schizophrenia: Hope or Hype?
Maju Mathew Koola
Indian Journal of Psychological Medicine
|
March 25, 2016
Methodological Issues in Cytokine Measurement in Schizophrenia
Maju Mathew Koola
Schizophrenia Research. Cognition
|
April 13, 2016
Kynurenine pathway and cognitive impairments in schizophrenia: Pharmacogenetics of galantamine and memantine
Maju Mathew Koola
Molecular Neuropsychiatry
|
November 7, 2018
Attenuated Mismatch Negativity in Attenuated Psychosis Syndrome Predicts Psychosis: Can Galantamine-Memantine Combination Prevent Psychosis?
Maju Mathew Koola
Asian Journal of Psychiatry
|
February 19, 2019
Antipsychotic-minocycline-acetylcysteine combination for positive, cognitive, and negative symptoms of schizophrenia
Maju Mathew Koola
Asian Journal of Psychiatry
|
November 19, 2017
Galantamine and memantine combination for cognition: Enough or more than enough to translate from murines and macaques to men with schizophrenia?
Maju Mathew Koola
Human Psychopharmacology
|
September 23, 2020
Alpha7 nicotinic-N-methyl-D-aspartate hypothesis in the treatment of schizophrenia and beyond
Maju Mathew Koola
Molecular Neuropsychiatry
|
January 16, 2019
Potential Role of Antipsychotic-Galantamine-Memantine Combination in the Treatment of Positive, Cognitive, and Negative Symptoms of Schizophrenia
Maju Mathew Koola
Page
of 8
Search research articles
Search
Showing results (1-10 of 71) with videos related to
Sort By:
Page
of 8
The Primary Care Companion for CNS Disorders
|
March 24, 2018
Galantamine-Memantine Combination for Cognitive Impairments Due to Electroconvulsive Therapy, Traumatic Brain Injury, and Neurologic and Psychiatric Disorders: Kynurenic Acid and Mismatch Negativity Target Engagement
Maju Mathew Koola
Schizophrenia Research
|
November 27, 2018
Can N‑acetylcysteine, varenicline, or the combination prevent psychosis by enhancing mismatch negativity?
Maju Mathew Koola
Indian Journal of Psychological Medicine
|
April 27, 2016
Cytokines in Schizophrenia: Hope or Hype?
Maju Mathew Koola
Indian Journal of Psychological Medicine
|
March 25, 2016
Methodological Issues in Cytokine Measurement in Schizophrenia
Maju Mathew Koola
Schizophrenia Research. Cognition
|
April 13, 2016
Kynurenine pathway and cognitive impairments in schizophrenia: Pharmacogenetics of galantamine and memantine
Maju Mathew Koola
Molecular Neuropsychiatry
|
November 7, 2018
Attenuated Mismatch Negativity in Attenuated Psychosis Syndrome Predicts Psychosis: Can Galantamine-Memantine Combination Prevent Psychosis?
Maju Mathew Koola
Asian Journal of Psychiatry
|
February 19, 2019
Antipsychotic-minocycline-acetylcysteine combination for positive, cognitive, and negative symptoms of schizophrenia
Maju Mathew Koola
Asian Journal of Psychiatry
|
November 19, 2017
Galantamine and memantine combination for cognition: Enough or more than enough to translate from murines and macaques to men with schizophrenia?
Maju Mathew Koola
Human Psychopharmacology
|
September 23, 2020
Alpha7 nicotinic-N-methyl-D-aspartate hypothesis in the treatment of schizophrenia and beyond
Maju Mathew Koola
Molecular Neuropsychiatry
|
January 16, 2019
Potential Role of Antipsychotic-Galantamine-Memantine Combination in the Treatment of Positive, Cognitive, and Negative Symptoms of Schizophrenia
Maju Mathew Koola
Page
of 8